Predictive factors of neoadjuvant immune checkpoint blockade in melanoma

This review describes the current body of literature and ongoing clinical trials examining neoadjuvant immune checkpoint inhibitors (ICI) for patients with resectable stage III and IV melanoma. Based on prior success in treating metastatic melanoma and as adjuvant therapy, ICIs are being explored in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarver, Melissa, Brown, Michael C., Rhodin, Kristen E., Salama, April K. S., Beasley, Georgia M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Melanoma Immunotherapy SF – Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122309/
https://www.ncbi.nlm.nih.gov/pubmed/34254900
http://dx.doi.org/10.1080/21645515.2021.1943987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122309/
https://www.ncbi.nlm.nih.gov/pubmed/34254900
http://dx.doi.org/10.1080/21645515.2021.1943987

Ejemplares similares